The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

St. Petersburg Research Institute of Vaccines and Sera

Status and phase: Completed; Phase 1

Conditions: Influenza

Treatments: Biological: Inactivated Split Influenza Vaccine; Biological: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT05126979

FMV-VGIR-1-001/15

Details and patient eligibility

About

Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years

Full description

All subjects will be followed up for 21 days post-randomization. The subjects will further be assessed at 2 days, 7 days, 21 days following the booster vaccination. Blood samples will be collected for reactogenicity and safety and immunogenicity assessments before injection and 21 days after vaccination.

Enrollment: 45 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Written informed consent of the volunteers to participate in the clinical study;
• Healthy volunteers (men and women) aged 18-60 years;
• Volunteers with a titer of antibodies to A(H1N1), A(H3N2) and B influenza viruses less than 1:40 in a HI test
• Volunteers able to fulfill requirements of the protocol (i.e. fill out the patient's diary, come to follow-up visits);
• Female participants were obliged to have negative pregnancy test results and use contraceptives throughout the follow-up period (complete contraception for women of reproductive age)

Exclusion criteria

• Allergic reactions to chicken protein or any previous influenza vaccination;
• Leukemia, cancer or a positive reaction to HIV infection, hepatitis B and C, syphilis in the medical history;
• Volunteers who received immunoglobulin or blood products within the last three months before the study;
• Guillain-Barre syndrome (acute polyneuropathy) in the medical history;
• Long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs for six months before the study;
• Any confirmed or suspected immunosuppressive or immunodeficiency condition;
• Respiratory, cardiovascular failure, impaired liver or kidney function found during a physical examination or laboratory tests at Visit 1;
• Severe birth defects or serious chronic diseases, including any clinically significant chronic diseases of lungs, kidneys, cardiovascular, nervous system, psychiatric diseases or metabolic disorders, confirmed by medical history or objective examination;
• Volunteers who are (or were) patients of a tuberculosis dispensary and/or narcological dispensary and/or neuropsychiatric dispensary
• acute infectious and/or non-infectious diseases at the time of inclusion in the study;
• Exacerbation of chronic diseases;
• Alcohol abuse and/or use of drugs in the past history;
• Pregnancy and lactation;
• Participation in another clinical study within the last 3 months

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

45 participants in 3 patient groups, including a placebo group

Flu-M (without a preservative)

Experimental group

Description:

15 volunteers were treated with the Flu-M inactivated split influenza vaccine without a preservative

Treatment:

Biological: Inactivated Split Influenza Vaccine

Flu-M (with a preservative)

Experimental group

Description:

15 volunteers were treated with the Flu-M inactivated split influenza vaccine with a preservative

Treatment:

Biological: Inactivated Split Influenza Vaccine

Placebo

Placebo Comparator group

Description:

15 volunteers were treated with a placebo

Treatment:

Biological: Placebo